Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs (Q37833072)

24 August 2017

1 reference

title

Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs (English)

1 reference

24 August 2017

1 reference

Masha S H Lam

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

31

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

164-192

1 reference

Safe Administration of Oral Chemotherapy

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Safety considerations and safe handling of oral chemotherapy agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Cost of chickenpox in Canada: part II. Cost of complicated cases and total economic impact. The Immunization Monitoring Program-Active (IMPACT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Oral chemotherapy in paediatric oncology in the UK: problems, perceptions and information needs of parents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Quality, safety and efficacy in the 'off-label' use of medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Patients' perspectives and safe handling of oral anticancer drugs at an Asian cancer center

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Population pharmacokinetics of oral busulfan in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Stability of cyclophosphamide in extemporaneous oral suspensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Effect of grapefruit juice intake on etoposide bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Chemical and functional analysis of hydroxyurea oral solutions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Blood levels of o,p′-DDD following administration in various vehicles after a single dose and during long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Effect of buffer and antioxidant on stability of a mercaptopurine suspension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Stability of sunitinib in oral suspension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Stability of an extemporaneous oral liquid aprepitant formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Distribution of tranexamic acid to plasma and saliva after oral administration and mouth rinsing: a pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Extemporaneous drug formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Safety of "inert" additives or excipients in paediatric medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Analysis of drug interactions involving fruit beverages and organic anion-transporting polypeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Medication administration through enteral feeding tubes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Enteral nutrition and drug administration, interactions, and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Practices of pharmacies that compound extemporaneous formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

The economic impact of a college of pharmacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Adherence to therapy with oral antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Nurses with dermal exposure to antineoplastic drugs: reproductive outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

A study of occupational exposure to antineoplastic drugs and fetal loss in nurses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Facilitating oral chemotherapy treatment and compliance through patient/family-focused education

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Effective methods of giving information in cancer: a systematic literature review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Development of the MASCC Teaching Tool for Patients Receiving Oral Agents for Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

Crushing or altering medications: what's happening in residential aged-care facilities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.2.164

21 January 2018

Identifiers

DOI

10.1592/PHCO.31.2.164

1 reference

24 August 2017

1 reference